Clinical Trial: Efficacy of Epidural Etanercept in the Treatment of Sciatica

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Efficacy of Epidural Etanercept in the Treatment of Sciatica

Brief Summary: Tumor necrosis factor (TNF)-alpha has been strongly implicated as a major contributing factor for the development of radiculopathy. In animal studies, the application of TNF-alpha to nerve roots results in pain behavior indicative of radiculopathy. The use of TNF-alpha inhibitors (etanercept and infliximab) have been shown to prevent this pain behavior. Open-label studies in humans have shown both etanercept and infliximab provide excellent, long-term relief in patients with acute radiculopathy from herniated disc. However, a recent placebo-controlled study failed to demonstrate any significant difference from placebo. The investigators have already established the safety of neuraxial etanercept in a trial that has just been completed (not yet published). The objective of this study is to determine whether small doses of epidural etanercept, an anti-TNF-a medication, is an effective treatment for LBP caused by nerve root irritation (i.e., radiculopathy).

Detailed Summary: As per the wishes of the Dept. of the Army and Walter Reed Army Medical Center Dept. of Clinical Investigation, patients will be randomized in a 3:1 ratio to receive 2 transforaminal epidural etanercept or saline injections at 2-week intervals. Both patients and physicians will be blinded as to the injectate and treatment group. There will be 3 study groups. Group I will receive either 2 mg of etanercept or saline per injection. Group II will receive either 4 mg of etanercept or saline per injection. Group III will receive either 6 mg of etanercept or saline per injection. In each group there will be 8 patients: 6 who receive etanercept and 2 who receive saline. As per a previous study we just completed, etanercept doses will not be escalated until all 6 patients have completed their 1-month follow-up visits without any evidence of toxicity or complications.
Sponsor: Johns Hopkins University

Current Primary Outcome: Visual analogue scale pain score, Oswestry disability index, medication intake [ Time Frame: 7 months ]

Original Primary Outcome: Visual analogue scale pain score Oswestry disability index, medication intake

Current Secondary Outcome: Global perceived effect, white blood cell count [ Time Frame: 7 months ]

Original Secondary Outcome: Global perceived effect, white blood cell count

Information By: Johns Hopkins University

Dates:
Date Received: August 14, 2006
Date Started: May 2006
Date Completion:
Last Updated: January 21, 2009
Last Verified: January 2009